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(A23187), which causes receptor-indepen-
dent nitric oxide release.
A single dose of IV MB (2 mg/kg, 20-
minute infusion time), as used by Leyh and
coworkers, was our first option in 1995.2
We are frequently asked about dose, infu-
sion, and route (venous or arterial). Many
colleagues tell us that they only observed a
transient effect using a 1 or 2 mg/kg IV
bolus. In our opinion, the IV MB bolus is a
rescue treatment. It is important to main-
tain a continuous infusion. In some cases,
we use a continuous infusion for more than
48 or 72 hours. Because the lethal doses of
MB are well known (40 mg/kg), it is pos-
sible to use higher doses if necessary. In
regard to the infusion route, in at least 1
anecdotal case, we observed a catastrophic
reaction to protamine without response to
norepinephrine or an IV MB bolus of 2
mg/kg. CPB was again established with
high flow, but we were unable to increase
the mean arterial pressure even with nor-
epinephrine infusion. The situation was
controlled only by using MB infusion in
the CPB arterial line again. Grayling and
Deakin3 presented this approach using MB
during CPB to treat valve endocarditis in a
case of ongoing septicemia.
In Argentina, Levin and colleagues4
performed a prospective, randomized study
including 638 patients who underwent car-
diac surgery, 56 (8.8%) of whom fulfilled
the vasoplegic postoperative criteria. The
overall mortality was 27 patients (4.2%), 6
(10.7%) of whom were in the vasoplegic
syndrome group and 21 (3.6%) of whom
were in the control group (P .02). The 56
patients with vasoplegic syndrome were
randomized to IV MB (1.5 mg/kg, 1-hour
infusion time) (28 patients) or placebo (28
patients). The general and surgical charac-
teristics of these 2 populations were quite
similar. There were no deaths in the MB
group and 6 deaths (21.4%) in the placebo
group. The MB resolution vasoplegia time
course was approximately 2 hours in all
cases. In those treated only with vasopres-
sors (8/28 patients, 28.6%), vasoplegia per-
sisted for more than 48 hours.
Since Gomes and colleagues5 described
vasoplegic syndrome, we speculate, as sur-
geons in undeveloped countries, whether
the vasoplegia was caused by some failure
in CPB material or drug quality control.
MB is increasingly used, for example in
liver transplantation. As there are few pa-
pers about its use in cardiac surgery it is
possible that cardiac surgical teams do not
consider vasoplegic syndrome to be a cat-
astrophic and unexpected problem, and it
may be underestimated.
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Reply to the Editor:
The results from the studies performed by
Evora and colleagues1,2 encouraged us to
use methylene blue (MB) as a rescue treat-
ment in catecholamine refractory vasople-
gia after cardiopulmonary bypass (CPB).3
We used an intravenous MB dose of 2
mg/kg as an infusion with a positive effect
in 92% of our patients. We selected this
dose because the majority of MB side ef-
fects obviously do not occur when a dose
of MB of 2 mg/kg or less is adminis-
tered.4-6 We have no experience with con-
tinuous MB infusion for more than 48
hours. Continuous MB infusion could be
an option for patients not responding to a
single dose of MB. However, more scien-
tific evidence is mandatory to define the
role of MB in the treatment of catechol-
amine refractory vasoplegia after CPB (eg,
multicenter, prospective, and randomized
studies). Even more important is a better
understanding of the mechanism triggering
vasoplegia after CPB to avoid this poten-
tially lethal complication, because a preop-
erative selection process to identify pa-
tients prone to vasoplegia after CPB could
result in prophylactic treatment with guan-
ylate cyclase inhibitors.
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